Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery

NCT01780220 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01780220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01780220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
Lead sponsor
UNICANCER
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2012
Completion date
January 7, 2022
Enrollment
47 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

biochemically-relapsing prostate adenocarcinoma following radical prostatectomy